januvia a glp 1 sitagliptin [TUSOM Hair loss with GLP-1 drugs

First, epidemiological data reveal that patients with T2D and cardiovascular disease receiving GLP-1RAs have substantial reductions in the risk of developing all-cause dementia

Prioritizing sufficient sleep and stress management to support holistic well-being

Since the newest drugs have proven so effective both at helping people lose weight and preventing other health problems doctors and policymakers want to expand access to GLP-1 medications

American society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)